Industry Pipeline - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Pipeline
Pre-Interphex 2010 Product Releases.

Pharmaceutical Technology
Volume 34, Issue 3, pp. 83-87

CHEMICALS, RAW MATERIALS, INTERMEDIATES, & EXCIPIENTS



High-purity inorganic salts
Jost manufactures high-purity ammonium sulfate in several grades, and the company also provides sodium phosphate and dodecahydrate. These inorganic salts are appropriate as biological buffers and as process intermediates for synthesizing active pharmaceutical ingredients. Jost manufactures more than 250 chemical salts in a facility registered with the US Food and Drug Administration. Jost Chemical, St. Louis, MO http://www.jostchemical.com/ tel. 314.428.4300



Excipient
The PanExcea MC200G performance excipient for oral disintegrating tablet applications combines two ingredients for rapid tablet disintegration and dispersion with good taste and texture. Designed for flexibility, PanExcea MC200G performance excipient enables high active-ingredient loading capacity and reduces tableting, licensing, and equipment expenses. Mallinckrodt Baker, Phillipsburg NJ http://www.mallbaker.com/ tel. 800.943.4747



Website
Roquette has launched a website for its pharmaceutical division. The site grants access to the company's excipient and active product lines and offers information about services. A formulation tool provides assistance to formulators from the product development cycle through to launch. The special services and support sections describe Roquette's application expertise. Roquette, Keokuk, IA http://www.roquette-pharma.com/ tel. 319-524-5757


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here